Z

Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267

Watchlist Manager
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Watchlist
Price: 10.41 CNY -1.23%
Market Cap: 12.5B CNY

Zhejiang Hisun Pharmaceutical Co Ltd
Gross Profit

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zhejiang Hisun Pharmaceutical Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Gross Profit
ÂĄ4.6B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
6%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Gross Profit
ÂĄ12B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Gross Profit
ÂĄ3.6B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Gross Profit
ÂĄ26.5B
CAGR 3-Years
14%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Gross Profit
ÂĄ11.6B
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Gross Profit
ÂĄ5.5B
CAGR 3-Years
111%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Hisun Pharmaceutical Co Ltd
Glance View

Market Cap
12.5B CNY
Industry
Pharmaceuticals

Zhejiang Hisun Pharmaceutical Co., Ltd. unfolds its story in the competitive arena of China's booming pharmaceutical industry. Founded in 1956, Hisun has gradually matured from a regional player into a recognized name in global generic and specialty drug manufacturing. The company's core strength lies in its integration across the pharmaceutical supply chain, which allows it to produce active pharmaceutical ingredients (APIs) while also scaling up to final dosage forms. Hisun capitalizes on its robust research and development capabilities, investing heavily in innovation to expand its diverse pharmaceutical product portfolio. Through strategic partnerships and collaborative ventures, such as alliances with leading biotech firms, Hisun not only enhances its technological footprint but fortifies its international presence, poised to address the increasing global demand for affordable healthcare solutions. In the sprawling marketplace, Hisun’s financial model is driven by its synergistic blend of producing generic medications and investing in biopharmaceuticals. The firm enjoys a lucrative revenue stream by tapping into the cost-effective production of APIs, which are integral to numerous medications worldwide. Through vertically integrated operations, the company achieves economies of scale, facilitating competitive pricing. Hisun’s foray into more value-added, complex generics and biosimilars further diversifies its income channels, transforming challenges into opportunities amid stringent global regulatory landscapes. By navigating these complexities, Hisun strengthens its market position, leveraging a balance between solid internal growth and strategic global outreach, thus sustaining its journey within the dynamic panorama of the pharmaceutical sector.

Intrinsic Value
12.46 CNY
Undervaluation 16%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Hisun Pharmaceutical Co Ltd's Gross Profit?
Gross Profit
4.6B CNY

Based on the financial report for Sep 30, 2025, Zhejiang Hisun Pharmaceutical Co Ltd's Gross Profit amounts to 4.6B CNY.

What is Zhejiang Hisun Pharmaceutical Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
6%

Over the last year, the Gross Profit growth was 23%. The average annual Gross Profit growth rates for Zhejiang Hisun Pharmaceutical Co Ltd have been -1% over the past three years , and 6% over the past ten years .

Back to Top